spacer
spacer

PDBsum entry 5izf

Go to PDB code: 
protein ligands links
Transferase PDB id
5izf

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
338 a.a.
Ligands
6J9-AZ1-DAR-ACA-
DAR-NH2
SO4 ×4
Waters ×44
PDB id:
5izf
Name: Transferase
Title: Complex of pka with the bisubstrate protein kinase inhibitor arc-1408
Structure: Camp-dependent protein kinase catalytic subunit alpha. Chain: a. Synonym: pka c-alpha. Engineered: yes. 6j9-zeu-dar-aca-dar-nh2. Chain: e. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: prkaca, pkaca. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Synthetic construct. Organism_taxid: 32630
Resolution:
2.10Å     R-factor:   0.232     R-free:   0.270
Authors: A.Pflug,E.Enkvist,A.Uri,R.A.Engh
Key ref: T.Ivan et al. (2016). Bifunctional Ligands for Inhibition of Tight-Binding Protein-Protein Interactions. Bioconjug Chem, 27, 1900-1910. PubMed id: 27389935 DOI: 10.1021/acs.bioconjchem.6b00293
Date:
25-Mar-16     Release date:   20-Jul-16    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
P17612  (KAPCA_HUMAN) -  cAMP-dependent protein kinase catalytic subunit alpha from Homo sapiens
Seq:
Struc:
351 a.a.
338 a.a.*
Key:    Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class: E.C.2.7.11.11  - cAMP-dependent protein kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction:
1. L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
2. L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
L-seryl-[protein]
+ ATP
= O-phospho-L-seryl-[protein]
+ ADP
+ H(+)
L-threonyl-[protein]
+ ATP
= O-phospho-L-threonyl-[protein]
+ ADP
+ H(+)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1021/acs.bioconjchem.6b00293 Bioconjug Chem 27:1900-1910 (2016)
PubMed id: 27389935  
 
 
Bifunctional Ligands for Inhibition of Tight-Binding Protein-Protein Interactions.
T.Ivan, E.Enkvist, B.Viira, G.B.Manoharan, G.Raidaru, A.Pflug, K.A.Alam, M.Zaccolo, R.A.Engh, A.Uri.
 
  ABSTRACT  
 
The acknowledged potential of small-molecule therapeutics targeting disease-related protein-protein interactions (PPIs) has promoted active research in this field. The strategy of using small molecule inhibitors (SMIs) to fight strong (tight-binding) PPIs tends to fall short due to the flat and wide interfaces of PPIs. Here we propose a biligand approach for disruption of strong PPIs. The potential of this approach was realized for disruption of the tight-binding (KD = 100 pM) tetrameric holoenzyme of cAMP-dependent protein kinase (PKA). Supported by X-ray analysis of cocrystals, bifunctional inhibitors (ARC-inhibitors) were constructed that simultaneously associated with both the ATP-pocket and the PPI interface area of the catalytic subunit of PKA (PKAc). Bifunctional inhibitor ARC-1411, possessing a KD value of 3 pM toward PKAc, induced the dissociation of the PKA holoenzyme with a low-nanomolar IC50, whereas the ATP-competitive inhibitor H89 bound to the PKA holoenzyme without disruption of the protein tetramer.
 

 

spacer

spacer